Insights On Drug Development

  1. Ask Us Anything: Matthew Bio On Driving Innovation In API Development 7/23/2026

    Join Matthew Bio, Ph.D., Chief Scientific Officer at Cambrex, as he shares how scientific collaboration and innovation are helping shape the future of pharmaceutical development.

  2. Ask Us Anything: Matt Bio On Peptide Commercialization Trends 7/23/2026

    Matt Bio, CSO of Cambrex and President of Snapdragon Chemistry, on the capacity bottleneck behind peptide shortages — and why moving from solid-phase to liquid-phase synthesis unlocks reactors already sitting idle around the world.

  3. Ask Us Anything: Matthew Schiesher On Validation During Tech Transfer 7/23/2026

    Matthew Schiesher, Head of R&D at Cambrex Charles City, on validating processes under the clock — and how running multiple sites in parallel shortens the path to launch when patients are waiting.

  4. Ask Us Anything: Päivi Tolstoy On The Future Of API Manufacturing 7/23/2026

    Päivi Tolstoy, Manager of Process Development at Cambrex Karlskoga, on why sustainability is the trend to watch in API manufacturing — and why the real question is how few steps it takes to build a complex molecule.

  5. Aligning Scientific Expertise To Accelerate Complex Biologics Programs 7/17/2026

    Complex biologics often outgrow traditional development platforms. Learn how an integrated development strategy can accelerate timelines while reducing risk.

  6. Mechanical Engineering Design Process For Combination Products 7/17/2026

    Mechanical engineering for combination drug-delivery devices demands more than good design — it requires data-driven risk management from specs through simulation. Learn how a structured phase approach ensures global manufacturing readiness.

  7. Considerations In Design And Development Of Novel Combination Drug-Delivery Devices 7/17/2026

    Poor scoping kills drug delivery device programs before they start. Learn how to define the right problem, assess risk early, and set boundaries that protect your timeline and budget.

  8. CLD Case Study: Complex Biologics – Bispecific Fusion Nanobody 7/17/2026

    See how a bispecific fusion nanobody (BFN) achieved BsAb titers above 7 g/L with 5 of 6 clones stable beyond 60 generations — from CLD through cGMP manufacturing.

  9. Three Keys To E&L Success: Study Design, Partner Selection, And Timing 7/16/2026

    Successful E&L planning starts before testing begins. Aligning study design, partner expertise, and timing helps teams focus on the right risks, avoid surprises, and support stronger development.

  10. Predicting Food Effects In Oral Drug Delivery Using PBPK Modeling 7/15/2026

    Learn how integrated PBPK and molecular dynamics modeling predicted an ~11% fed-state Cmax increase for fenofibrate, giving formulation teams earlier, mechanistic insight into food-dependent absorption.